MAPT and tauopathy: In previous studies, using an acute treatment paradigm (2–3 injections of 4E6 tau antibody) in htau and JNPL3 tauopathy models, soluble tau was primarily being cleared.12–14 Although these studies cannot be directly compared because the antibodies are not the same, it seems logical that a chronic vs. acute treatment would affect insoluble vs. soluble pools of tau, respectively.